Black Diamond Therapeutics, Inc. (BDTX)

Add to research

Evaluation: Based on all recent filings, financial statements, and news.

See full evaluation
Company performance
Add to research
View more

Current Price

as of Mar 21, 2025

$1.78

P/E Ratio

N/A

Market Cap

$100.86M

Description
Add to research
View more

Black Diamond Therapeutics, Inc. is a precision oncology medicine company, which engages in discovery and development of small molecule, masterkey therapies. The company was founded by David M. Epstein and Elizabeth Buck in 2014 and is headquartered in Cambridge, MA.

Metrics
Add to research
View more

Overview

  • HQCambridge, MA
  • SectorHealth Technology
  • IndustryBiotechnology
  • TickerBDTX
  • Price$1.78-5.32%

Trading Information

  • Market cap$100.86M
  • Float76.17%
  • Average Daily Volume (1m)7,519,989
  • Average Daily Volume (3m)3,117,634
  • EPS-$1.27

Company

  • RevenueN/A
  • Rev growth (1yr)N/A
  • Net income-$69.68M
  • Gross marginN/A
  • EBITDA marginN/A
  • EBITDA-$75.49M
  • EV$41.37M
  • EV/RevenueN/A
  • P/EN/A
  • P/SN/A
  • P/B1.28
  • Debt/Equity26.64
Documents
Add to research
View more
SEC Filings
8-K (2025-03-19)
8-K (2025-03-06)
8-K (2024-11-05)
8-K (2024-10-07)
8-K (2024-09-23)
8-K (2024-08-06)
8-K (2024-06-06)
8-K (2024-05-09)
8-K (2024-04-11)
8-K (2024-03-12)
8-K (2024-01-18)
8-K (2024-01-04)
8-K (2023-12-13)
8-K (2023-11-06)
8-K (2023-09-18)
8-K (2023-08-11)
8-K (2023-06-30)
8-K (2023-06-27)
8-K (2023-05-16)
8-K (2023-05-09)
8-K (2023-03-09)
10-Q (2024-11-05)
10-Q (2024-08-06)
10-Q (2024-05-09)
10-Q (2023-11-06)
10-Q (2023-08-11)
10-Q (2023-05-09)
10-K (2025-03-06)
10-K (2024-03-12)
10-K (2023-03-09)
Factset Street Account
Black Diamond Therapeutics reports Q3 EPS ($0.45) vs FactSet ($0.49) [6 est, ($0.64)-(0.40)] - 8-K ($1.90, 0.00) (2023-11-06T12:19:44Z)
Black Diamond Therapeutics reports dose escalation data demonstrating durable responses in patients with NSCLC from phase 1 trial of BDTX-1535 ($2.29, 0.00) (2023-10-14T22:32:56Z)